Dr. Backes Discusses PARP Inhibitor Combinations in Ovarian Cancer

Dr. Backes Discusses her Experience With PARP Inhibitors in Ovarian CancerПодробнее

Dr. Backes on Financial Toxicity Considerations in Ovarian CancerПодробнее

Dr. Backes on Treatment Selection With PARP Inhibitors in Ovarian CancerПодробнее

Dr. Backes on Quality of Life With PARP Inhibitors in Ovarian CancerПодробнее

7 Common Ovarian Cancer Signs That You Should Never IgnoreПодробнее

Dr. Hardesty on Bevacizumab/PARP Inhibitor Combination in Ovarian CancerПодробнее

Combinations With PARP Inhibitors for Ovarian CancerПодробнее

Dr. Berek Discusses the Impact of PARP Inhibitors on Ovarian CancerПодробнее

PARP Inhibitor Combinations and Future of Ovarian CancerПодробнее

Challenges With PARP Inhibitors in Ovarian CancerПодробнее

Ongoing Clinical Trials with PARP Inhibitors in Ovarian CancerПодробнее

Combination Regimens May Improve Responses in Ovarian CancerПодробнее

Precision Medicine in Ovarian Cancer With PARP Inhibitor Therapy and Companion DiagnosticsПодробнее

Dr. McCann on Combination Trials With PARP Inhibitors in Ovarian CancerПодробнее

PARP Combination Therapies in Ovarian CancerПодробнее

Is It Time to Change Upfront Chemotherapy for Ovarian Cancer?Подробнее

The Advanced Ovarian Cancer Treatment Palette: Candid Conversations on PARP InhibitorsПодробнее

Dr. Moore on Immunotherapy and PARP Combinations in BRCA-Mutated Ovarian CancerПодробнее

Dr. Hays on Potential for PARP Inhibitor Combinations in Ovarian CancerПодробнее